| Literature DB >> 28279425 |
Alexandra J Ritts1, Robert F Cornell2, Kris Swiger3, Jai Singh3, Stacey Goodman2, Daniel J Lenihan4.
Abstract
Cardiac amyloidosis is a complex and vexing clinical condition that requires a high degree of suspicion for the diagnosis with a substantial amount of discipline to discern the extent of disease and the best available therapy. There is a complex interplay between multiple organ systems, and the clinical presentation may involve a myriad of confusing clinical symptoms. The diagnosis of cardiac amyloidosis can be confirmed with a combination of physical findings, cardiac biomarkers, noninvasive testing, and, if necessary, myocardial biopsy. Genetic testing is critical to establish the type of amyloidosis.Entities:
Keywords: Cardiac amyloidosis; Cardiotoxicity; Immunomodulatory drugs; Multiple myeloma; Proteasome inhibitors; TTR
Mesh:
Year: 2017 PMID: 28279425 DOI: 10.1016/j.hfc.2016.12.003
Source DB: PubMed Journal: Heart Fail Clin ISSN: 1551-7136 Impact factor: 3.179